• 1. Isatin as a 2-aminobenzaldehyde surrogate: transition metal-free efficient synthesis of 2-(2′-aminophenyl)benzothiazole derivatives
  Manpreet Singh,Vaishali,Avijit Kumar Paul,Virender Singh Org. Biomol. Chem. 2020 18 4459
• 2. Cu(ii)-catalyzed C–N coupling of 2-aminobenzothiazoles with boronic acids at room temperature
  Sankaran Radhika,Aravind Chandravarkar,Gopinathan Anilkumar RSC Adv. 2023 13 17188
• 3. Contemporary progress in the synthesis and reactions of 2-aminobenzothiazole: a review
  Tulshiram L. Dadmal,Sangita D. Katre,Mustapha C. Mandewale,Ravindra M. Kumbhare New J. Chem. 2018 42 776
• 4. Design, complexing and catalytic properties of phosphorus thiazoles and benzothiazoles: a concise overview
  Jean-Pierre Majoral,Maria Zablocka,Marek Koprowski,Aurelien Hameau,Xiangyang Shi,Serge Mignani,Anne-Marie Caminade New J. Chem. 2019 43 16785
• 5. Conformational preferences in model antiviral compounds: A spectroscopic and computational study of phenylurea and 1,3-diphenylurea
  R. Emery,N. A. Macleod,L. C. Snoek,J. P. Simons Phys. Chem. Chem. Phys. 2004 6 2816

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives N-phenylureas

Frentizole (CAS No. 26130-02-9): A Comprehensive Overview

Frentizole, with the Chemical Abstracts Service (CAS) number 26130-02-9, is a compound that has garnered significant attention in the field of medicinal chemistry and pharmaceutical research. This compound is known for its unique chemical structure and potential therapeutic applications, making it a subject of extensive study in both academic and industrial settings.

The chemical structure of Frentizole is characterized by its specific molecular formula and functional groups, which contribute to its pharmacological properties. Recent advancements in analytical techniques have allowed researchers to gain deeper insights into the molecular dynamics and interactions of Frentizole. These studies have highlighted its potential as a lead compound for the development of novel drugs targeting various diseases.

In the realm of medicinal chemistry, Frentizole has shown promising results in preclinical studies. Its ability to modulate specific biological pathways has been extensively investigated, with a focus on its potential as an anti-inflammatory agent and its role in neuroprotection. Research published in leading scientific journals has demonstrated that Frentizole can effectively reduce inflammation and oxidative stress, making it a valuable candidate for the treatment of conditions such as Alzheimer's disease and multiple sclerosis.

The pharmacokinetic properties of Frentizole have also been a subject of interest. Studies have shown that it exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles, which are crucial for its therapeutic efficacy. These properties make it an attractive candidate for further clinical development. Additionally, the compound's low toxicity and high selectivity enhance its safety profile, reducing the risk of adverse effects in patients.

One of the key areas of research involving Frentizole is its potential as an antiviral agent. Recent studies have explored its ability to inhibit viral replication, particularly in the context of emerging viral infections. This has led to increased interest in developing Frentizole-based therapies for viral diseases, including those caused by RNA viruses such as influenza and coronaviruses. The antiviral activity of Frentizole is attributed to its ability to interfere with viral entry and replication processes, making it a promising candidate for broad-spectrum antiviral applications.

Beyond its therapeutic applications, Frentizole has also been studied for its potential use in diagnostic imaging. Its unique chemical properties make it suitable for use as a contrast agent in various imaging modalities, such as magnetic resonance imaging (MRI) and computed tomography (CT). This dual functionality—therapeutic and diagnostic—positions Frentizole as a versatile compound with broad applications in medical research and clinical practice.

The development of novel formulations of Frentizole has also been an area of active research. Scientists are exploring different delivery systems to enhance the bioavailability and efficacy of the compound. Nanotechnology-based approaches, such as liposomal formulations and nanoparticle delivery systems, have shown promise in improving the pharmacological properties of Frentizole. These advanced delivery systems can target specific tissues or cells, thereby increasing the therapeutic index and reducing systemic side effects.

In conclusion, Frentizole (CAS No. 26130-02-9) is a multifaceted compound with significant potential in various areas of medical research and pharmaceutical development. Its unique chemical structure, favorable pharmacokinetic properties, and diverse therapeutic applications make it an exciting subject for ongoing research. As new findings continue to emerge, the role of Frentizole in advancing medical science is likely to expand, contributing to the development of innovative treatments for a wide range of diseases.

• 63650-40-8(N-(6-Hydroxy-1,3-benzothiazol-2-yl)-N'-(4-methylphenyl)urea)
• 26135-33-1(1-(6-methoxy-1,3-benzothiazol-2-yl)-3-(3-methylphenyl)urea)
• 81108-80-7(UREA, N-(4-CHLOROPHENYL)-N'-(6-ETHOXY-2-BENZOTHIAZOLYL)-)
• 1820-02-6(Thiourea, N-2-benzothiazolyl-N'-(4-methoxyphenyl)-)
• 196925-51-6(1-(3,4-dichlorophenyl)-3-(6-methoxy-1,3-benzothiazol-2-yl)urea)
• 32294-42-1(1-(6-methoxybenzo[d]thiazol-2-yl)-3-phenylthiourea)
• 58668-51-2(2-[(Phenylcarbamoyl)amino]-1,3-benzothiazol-6-yl phenylcarbamate)
• 26135-12-6(1-(1,3-benzothiazol-2-yl)-3-phenylurea)
• 894427-13-5(Urea, N-(2-amino-6-benzothiazolyl)-N'-(3-methoxyphenyl)-)
• 26130-03-0(1-(4-Chlorophenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea)